Abstract

Using a receptor binding assay for [ 3H](+)-5-methyl-10,11-dihydro-5 H-dibenzo[ a,d]cyclohepten-5-10-imine (MK-801) the pharmacology of spinal cord NMDA receptors was compared to that of NMDA receptors in the cerebral cortex. The affinities of glutamate site agonists l-glutamate, l-aspartate, ibotenic acid, NMDA and quinolinic acid for stimulation of [ 3H]MK-801 binding were 6–10 times lower in the spinal cord and the efficacy of quinolinic acid was 50% of that of the other agonists in this region. Also the affinities of glycine site agonists glycine, d-serine, d-alanine and l-serine were lower in the spinal cord as were the affinities of the non-competitive antagonists phencyclidine, (±)-cyclazocine and dextromethorphan. The divalent cations Zn 2+, Mg 2+ and Ca 2+ had 4–8 times lower affinity for spinal NMDA receptors while the affinity of Co 2+ was 50 times lower. The affinity of [ 3H]MK-801 was 2.5-fold lower in the spinal cord. These data show that spinal cord NMDA receptors show qualitative and quantitative differences compared to those in the cerebral cortex.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call